HEADER TRANSFERASE 16-NOV-07 3BEA
TITLE CFMS TYROSINE KINASE (TIE2 KID) IN COMPLEX WITH A PYRIMIDINOPYRIDONE
TITLE 2 INHIBITOR
COMPND MOL_ID: 1;
COMPND 2 MOLECULE: MACROPHAGE COLONY-STIMULATING FACTOR 1 RECEPTOR;
COMPND 3 CHAIN: A;
COMPND 4 SYNONYM: CSF-1-R, FMS PROTO-ONCOGENE, C-FMS, CD115 ANTIGEN;
COMPND 5 EC: 2.7.10.1;
COMPND 6 ENGINEERED: YES;
COMPND 7 MUTATION: YES
SOURCE MOL_ID: 1;
SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS;
SOURCE 3 ORGANISM_COMMON: HUMAN;
SOURCE 4 GENE: CSF1R, FMS;
SOURCE 5 EXPRESSION_SYSTEM: SPODOPTERA FRUGIPERDA
KEYWDS KINASE DOMAIN, INHIBITOR, TRANSFERASE, JUXTAMEMBRANE DOMAIN, ATP-
KEYWDS 2 BINDING, GLYCOPROTEIN, IMMUNOGLOBULIN DOMAIN, NUCLEOTIDE-BINDING,
KEYWDS 3 PHOSPHOPROTEIN, POLYMORPHISM, PROTO-ONCOGENE, RECEPTOR,
KEYWDS 4 TRANSMEMBRANE, TYROSINE-PROTEIN KINASE
EXPDTA X-RAY DIFFRACTION
AUTHOR C.SCHUBERT
REVDAT 5 30-AUG-23 3BEA 1 REMARK
REVDAT 4 20-OCT-21 3BEA 1 REMARK SEQADV
REVDAT 3 02-AUG-17 3BEA 1 SOURCE
REVDAT 2 24-FEB-09 3BEA 1 VERSN
REVDAT 1 15-JUL-08 3BEA 0
JRNL AUTH H.HUANG,D.A.HUTTA,H.HU,R.L.DESJARLAIS,C.SCHUBERT,
JRNL AUTH 2 I.P.PETROUNIA,M.A.CHAIKIN,C.L.MANTHEY,M.R.PLAYER
JRNL TITL DESIGN AND SYNTHESIS OF A PYRIDO[2,3-D]PYRIMIDIN-5-ONE CLASS
JRNL TITL 2 OF ANTI-INFLAMMATORY FMS INHIBITORS.
JRNL REF BIOORG.MED.CHEM.LETT. V. 18 2355 2008
JRNL REFN ISSN 0960-894X
JRNL PMID 18342505
JRNL DOI 10.1016/J.BMCL.2008.02.070
REMARK 2
REMARK 2 RESOLUTION. 2.02 ANGSTROMS.
REMARK 3
REMARK 3 REFINEMENT.
REMARK 3 PROGRAM : CNX 2005
REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE-
REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU,
REMARK 3 : READ,RICE,SIMONSON,WARREN,ACCELRYS
REMARK 3 : SOFTWARE INC.(BADGER,BERARD,KUMAR,SZALMA,
REMARK 3 : YIP,DZAKULA)
REMARK 3
REMARK 3 DATA USED IN REFINEMENT.
REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.02
REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 31.13
REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000
REMARK 3 DATA CUTOFF HIGH (ABS(F)) : 2313407.900
REMARK 3 DATA CUTOFF LOW (ABS(F)) : 0.0000
REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 88.2
REMARK 3 NUMBER OF REFLECTIONS : 20630
REMARK 3
REMARK 3 FIT TO DATA USED IN REFINEMENT.
REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT
REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM
REMARK 3 R VALUE (WORKING + TEST SET) : 0.193
REMARK 3 R VALUE (WORKING SET) : 0.193
REMARK 3 FREE R VALUE : 0.230
REMARK 3 FREE R VALUE TEST SET SIZE (%) : 7.300
REMARK 3 FREE R VALUE TEST SET COUNT : 1514
REMARK 3 ESTIMATED ERROR OF FREE R VALUE : 0.006
REMARK 3
REMARK 3 FIT/AGREEMENT OF MODEL WITH ALL DATA.
REMARK 3 R VALUE (WORKING + TEST SET, NO CUTOFF) : NULL
REMARK 3 R VALUE (WORKING SET, NO CUTOFF) : NULL
REMARK 3 FREE R VALUE (NO CUTOFF) : NULL
REMARK 3 FREE R VALUE TEST SET SIZE (%, NO CUTOFF) : NULL
REMARK 3 FREE R VALUE TEST SET COUNT (NO CUTOFF) : NULL
REMARK 3 ESTIMATED ERROR OF FREE R VALUE (NO CUTOFF) : NULL
REMARK 3 TOTAL NUMBER OF REFLECTIONS (NO CUTOFF) : 24175
REMARK 3
REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN.
REMARK 3 TOTAL NUMBER OF BINS USED : 6
REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 2.02
REMARK 3 BIN RESOLUTION RANGE LOW (A) : 2.13
REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 49.20
REMARK 3 REFLECTIONS IN BIN (WORKING SET) : 1860
REMARK 3 BIN R VALUE (WORKING SET) : 0.2200
REMARK 3 BIN FREE R VALUE : 0.2490
REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : 6.30
REMARK 3 BIN FREE R VALUE TEST SET COUNT : 125
REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : 0.022
REMARK 3
REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT.
REMARK 3 PROTEIN ATOMS : 2461
REMARK 3 NUCLEIC ACID ATOMS : 0
REMARK 3 HETEROGEN ATOMS : 53
REMARK 3 SOLVENT ATOMS : 169
REMARK 3
REMARK 3 B VALUES.
REMARK 3 FROM WILSON PLOT (A**2) : 16.70
REMARK 3 MEAN B VALUE (OVERALL, A**2) : 30.00
REMARK 3 OVERALL ANISOTROPIC B VALUE.
REMARK 3 B11 (A**2) : -3.18000
REMARK 3 B22 (A**2) : -3.18000
REMARK 3 B33 (A**2) : 6.36000
REMARK 3 B12 (A**2) : -0.69000
REMARK 3 B13 (A**2) : 0.00000
REMARK 3 B23 (A**2) : 0.00000
REMARK 3
REMARK 3 ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.22
REMARK 3 ESD FROM SIGMAA (A) : 0.15
REMARK 3 LOW RESOLUTION CUTOFF (A) : 5.00
REMARK 3
REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR.
REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : 0.27
REMARK 3 ESD FROM C-V SIGMAA (A) : 0.15
REMARK 3
REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES.
REMARK 3 BOND LENGTHS (A) : 0.005
REMARK 3 BOND ANGLES (DEGREES) : 0.800
REMARK 3 DIHEDRAL ANGLES (DEGREES) : 20.80
REMARK 3 IMPROPER ANGLES (DEGREES) : 0.680
REMARK 3
REMARK 3 ISOTROPIC THERMAL MODEL : RESTRAINED
REMARK 3
REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA
REMARK 3 MAIN-CHAIN BOND (A**2) : 1.560 ; 1.500
REMARK 3 MAIN-CHAIN ANGLE (A**2) : 2.490 ; 2.000
REMARK 3 SIDE-CHAIN BOND (A**2) : 2.110 ; 2.000
REMARK 3 SIDE-CHAIN ANGLE (A**2) : 3.050 ; 2.500
REMARK 3
REMARK 3 BULK SOLVENT MODELING.
REMARK 3 METHOD USED : FLAT MODEL
REMARK 3 KSOL : 0.36
REMARK 3 BSOL : 45.87
REMARK 3
REMARK 3 NCS MODEL : NULL
REMARK 3
REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT
REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL
REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL
REMARK 3
REMARK 3 PARAMETER FILE 1 : PROTEIN_REP.PARAM
REMARK 3 PARAMETER FILE 2 : INH.PAR
REMARK 3 PARAMETER FILE 3 : WATER_REP.PARAM
REMARK 3 PARAMETER FILE 4 : ION.PARAM
REMARK 3 PARAMETER FILE 5 : NULL
REMARK 3 TOPOLOGY FILE 1 : PROTEIN.TOP
REMARK 3 TOPOLOGY FILE 2 : INH.TOP
REMARK 3 TOPOLOGY FILE 3 : WATER.TOP
REMARK 3 TOPOLOGY FILE 4 : ION.TOP
REMARK 3 TOPOLOGY FILE 5 : NULL
REMARK 3
REMARK 3 OTHER REFINEMENT REMARKS: NULL
REMARK 4
REMARK 4 3BEA COMPLIES WITH FORMAT V. 3.30, 13-JUL-11
REMARK 100
REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 03-DEC-07.
REMARK 100 THE DEPOSITION ID IS D_1000045411.
REMARK 200
REMARK 200 EXPERIMENTAL DETAILS
REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION
REMARK 200 DATE OF DATA COLLECTION : 14-JUL-05
REMARK 200 TEMPERATURE (KELVIN) : 100
REMARK 200 PH : 5.2
REMARK 200 NUMBER OF CRYSTALS USED : 1
REMARK 200
REMARK 200 SYNCHROTRON (Y/N) : Y
REMARK 200 RADIATION SOURCE : APS
REMARK 200 BEAMLINE : 17-BM
REMARK 200 X-RAY GENERATOR MODEL : NULL
REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M
REMARK 200 WAVELENGTH OR RANGE (A) : 1.0
REMARK 200 MONOCHROMATOR : SAGITALLY FOCUSED SI(111)
REMARK 200 OPTICS : NULL
REMARK 200
REMARK 200 DETECTOR TYPE : CCD
REMARK 200 DETECTOR MANUFACTURER : MAR CCD 165 MM
REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO
REMARK 200 DATA SCALING SOFTWARE : SCALEPACK
REMARK 200
REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 20630
REMARK 200 RESOLUTION RANGE HIGH (A) : 2.020
REMARK 200 RESOLUTION RANGE LOW (A) : 31.130
REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000
REMARK 200
REMARK 200 OVERALL.
REMARK 200 COMPLETENESS FOR RANGE (%) : 87.9
REMARK 200 DATA REDUNDANCY : 3.200
REMARK 200 R MERGE (I) : 0.06200
REMARK 200 R SYM (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR THE DATA SET : 17.7000
REMARK 200
REMARK 200 IN THE HIGHEST RESOLUTION SHELL.
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.02
REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.09
REMARK 200 COMPLETENESS FOR SHELL (%) : 52.3
REMARK 200 DATA REDUNDANCY IN SHELL : 2.00
REMARK 200 R MERGE FOR SHELL (I) : 0.23000
REMARK 200 R SYM FOR SHELL (I) : NULL
REMARK 200 <I/SIGMA(I)> FOR SHELL : 3.400
REMARK 200
REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH
REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT
REMARK 200 SOFTWARE USED: CNX 2005
REMARK 200 STARTING MODEL: PDB ENTRY 2I1M
REMARK 200
REMARK 200 REMARK: NULL
REMARK 280
REMARK 280 CRYSTAL
REMARK 280 SOLVENT CONTENT, VS (%): 49.80
REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.45
REMARK 280
REMARK 280 CRYSTALLIZATION CONDITIONS: PEG 3350, SODIUM ACETATE, LI2SO4, PH
REMARK 280 5.2, VAPOR DIFFUSION, HANGING DROP, TEMPERATURE 298K
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY
REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: H 3
REMARK 290
REMARK 290 SYMOP SYMMETRY
REMARK 290 NNNMMM OPERATOR
REMARK 290 1555 X,Y,Z
REMARK 290 2555 -Y,X-Y,Z
REMARK 290 3555 -X+Y,-X,Z
REMARK 290 4555 X+2/3,Y+1/3,Z+1/3
REMARK 290 5555 -Y+2/3,X-Y+1/3,Z+1/3
REMARK 290 6555 -X+Y+2/3,-X+1/3,Z+1/3
REMARK 290 7555 X+1/3,Y+2/3,Z+2/3
REMARK 290 8555 -Y+1/3,X-Y+2/3,Z+2/3
REMARK 290 9555 -X+Y+1/3,-X+2/3,Z+2/3
REMARK 290
REMARK 290 WHERE NNN -> OPERATOR NUMBER
REMARK 290 MMM -> TRANSLATION VECTOR
REMARK 290
REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS
REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM
REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY
REMARK 290 RELATED MOLECULES.
REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000
REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000
REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000
REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000
REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000
REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 0.00000
REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 40.57000
REMARK 290 SMTRY2 4 0.000000 1.000000 0.000000 23.42310
REMARK 290 SMTRY3 4 0.000000 0.000000 1.000000 48.55000
REMARK 290 SMTRY1 5 -0.500000 -0.866025 0.000000 40.57000
REMARK 290 SMTRY2 5 0.866025 -0.500000 0.000000 23.42310
REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 48.55000
REMARK 290 SMTRY1 6 -0.500000 0.866025 0.000000 40.57000
REMARK 290 SMTRY2 6 -0.866025 -0.500000 0.000000 23.42310
REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 48.55000
REMARK 290 SMTRY1 7 1.000000 0.000000 0.000000 0.00000
REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 46.84620
REMARK 290 SMTRY3 7 0.000000 0.000000 1.000000 97.10000
REMARK 290 SMTRY1 8 -0.500000 -0.866025 0.000000 0.00000
REMARK 290 SMTRY2 8 0.866025 -0.500000 0.000000 46.84620
REMARK 290 SMTRY3 8 0.000000 0.000000 1.000000 97.10000
REMARK 290 SMTRY1 9 -0.500000 0.866025 0.000000 0.00000
REMARK 290 SMTRY2 9 -0.866025 -0.500000 0.000000 46.84620
REMARK 290 SMTRY3 9 0.000000 0.000000 1.000000 97.10000
REMARK 290
REMARK 290 REMARK: NULL
REMARK 300
REMARK 300 BIOMOLECULE: 1
REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM
REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN
REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON
REMARK 300 BURIED SURFACE AREA.
REMARK 350
REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN
REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE
REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS
REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND
REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN.
REMARK 350
REMARK 350 BIOMOLECULE: 1
REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: MONOMERIC
REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: MONOMERIC
REMARK 350 SOFTWARE USED: PISA
REMARK 350 APPLY THE FOLLOWING TO CHAINS: A
REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000
REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000
REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000
REMARK 375
REMARK 375 SPECIAL POSITION
REMARK 375 THE FOLLOWING ATOMS ARE FOUND TO BE WITHIN 0.15 ANGSTROMS
REMARK 375 OF A SYMMETRY RELATED ATOM AND ARE ASSUMED TO BE ON SPECIAL
REMARK 375 POSITIONS.
REMARK 375
REMARK 375 ATOM RES CSSEQI
REMARK 375 HOH A1079 LIES ON A SPECIAL POSITION.
REMARK 465
REMARK 465 MISSING RESIDUES
REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE
REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN
REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.)
REMARK 465
REMARK 465 M RES C SSSEQI
REMARK 465 GLY A 535
REMARK 465 VAL A 536
REMARK 465 ASP A 537
REMARK 465 TYR A 538
REMARK 465 LYS A 539
REMARK 465 TYR A 540
REMARK 465 LYS A 541
REMARK 465 GLN A 542
REMARK 465 LYS A 543
REMARK 465 PRO A 544
REMARK 465 LYS A 545
REMARK 465 TYR A 546
REMARK 465 GLU A 683
REMARK 465 THR A 684
REMARK 465 ASP A 685
REMARK 465 PRO A 686
REMARK 465 ALA A 687
REMARK 465 PHE A 688
REMARK 465 ALA A 689
REMARK 465 ILE A 690
REMARK 465 ALA A 691
REMARK 465 ASN A 692
REMARK 465 ASP A 922
REMARK 500
REMARK 500 GEOMETRY AND STEREOCHEMISTRY
REMARK 500 SUBTOPIC: TORSION ANGLES
REMARK 500
REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS:
REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER;
REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE).
REMARK 500
REMARK 500 STANDARD TABLE:
REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2)
REMARK 500
REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI-
REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400
REMARK 500
REMARK 500 M RES CSSEQI PSI PHI
REMARK 500 GLU A 557 15.28 54.25
REMARK 500 LEU A 569 78.23 49.92
REMARK 500 PRO A 570 -159.42 -57.70
REMARK 500 GLU A 573 4.57 -65.84
REMARK 500 ASP A 608 52.66 33.55
REMARK 500 HIS A 623 -151.73 -107.49
REMARK 500 VAL A 681 -99.64 -76.75
REMARK 500 ASP A 778 45.57 -150.36
REMARK 500 THR A 787 -163.78 -112.45
REMARK 500
REMARK 500 REMARK: NULL
REMARK 800
REMARK 800 SITE
REMARK 800 SITE_IDENTIFIER: AC1
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 1
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC2
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 2
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC3
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 4
REMARK 800
REMARK 800 SITE_IDENTIFIER: AC4
REMARK 800 EVIDENCE_CODE: SOFTWARE
REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE IXH A 923
REMARK 900
REMARK 900 RELATED ENTRIES
REMARK 900 RELATED ID: 2I0V RELATED DB: PDB
REMARK 900 AUTOINHIBITED FORM, COMPLEXED WITH QUINOLONE INHIBITOR
REMARK 900 RELATED ID: 2I1M RELATED DB: PDB
REMARK 900 AUTOINHIBITED FORM, COMPLEXED WITH ARYLAMIDE INHIBITOR
REMARK 900 RELATED ID: 2I0Y RELATED DB: PDB
REMARK 900 AUTOINHIBITED FORM, COMPLEXED WITH ARYLAMIDE INHIBITOR
REMARK 900 RELATED ID: 2OGV RELATED DB: PDB
REMARK 900 AUTOINHIBITED FORM, APO
DBREF 3BEA A 538 678 UNP P07333 CSF1R_HUMAN 538 678
DBREF 3BEA A 679 697 UNP Q02763 TIE2_HUMAN 917 935
DBREF 3BEA A 753 922 UNP P07333 CSF1R_HUMAN 753 922
SEQADV 3BEA GLY A 535 UNP P07333 EXPRESSION TAG
SEQADV 3BEA VAL A 536 UNP P07333 EXPRESSION TAG
SEQADV 3BEA ASP A 537 UNP P07333 EXPRESSION TAG
SEQADV 3BEA LEU A 695 UNP Q02763 ALA 933 ENGINEERED MUTATION
SEQRES 1 A 333 GLY VAL ASP TYR LYS TYR LYS GLN LYS PRO LYS TYR GLN
SEQRES 2 A 333 VAL ARG TRP LYS ILE ILE GLU SER TYR GLU GLY ASN SER
SEQRES 3 A 333 TYR THR PHE ILE ASP PRO THR GLN LEU PRO TYR ASN GLU
SEQRES 4 A 333 LYS TRP GLU PHE PRO ARG ASN ASN LEU GLN PHE GLY LYS
SEQRES 5 A 333 THR LEU GLY ALA GLY ALA PHE GLY LYS VAL VAL GLU ALA
SEQRES 6 A 333 THR ALA PHE GLY LEU GLY LYS GLU ASP ALA VAL LEU LYS
SEQRES 7 A 333 VAL ALA VAL LYS MET LEU LYS SER THR ALA HIS ALA ASP
SEQRES 8 A 333 GLU LYS GLU ALA LEU MET SER GLU LEU LYS ILE MET SER
SEQRES 9 A 333 HIS LEU GLY GLN HIS GLU ASN ILE VAL ASN LEU LEU GLY
SEQRES 10 A 333 ALA CYS THR HIS GLY GLY PRO VAL LEU VAL ILE THR GLU
SEQRES 11 A 333 TYR CYS CYS TYR GLY ASP LEU LEU ASN PHE LEU ARG ARG
SEQRES 12 A 333 LYS SER ARG VAL LEU GLU THR ASP PRO ALA PHE ALA ILE
SEQRES 13 A 333 ALA ASN SER THR LEU SER THR ARG ASP LEU LEU HIS PHE
SEQRES 14 A 333 SER SER GLN VAL ALA GLN GLY MET ALA PHE LEU ALA SER
SEQRES 15 A 333 LYS ASN CYS ILE HIS ARG ASP VAL ALA ALA ARG ASN VAL
SEQRES 16 A 333 LEU LEU THR ASN GLY HIS VAL ALA LYS ILE GLY ASP PHE
SEQRES 17 A 333 GLY LEU ALA ARG ASP ILE MET ASN ASP SER ASN TYR ILE
SEQRES 18 A 333 VAL LYS GLY ASN ALA ARG LEU PRO VAL LYS TRP MET ALA
SEQRES 19 A 333 PRO GLU SER ILE PHE ASP CYS VAL TYR THR VAL GLN SER
SEQRES 20 A 333 ASP VAL TRP SER TYR GLY ILE LEU LEU TRP GLU ILE PHE
SEQRES 21 A 333 SER LEU GLY LEU ASN PRO TYR PRO GLY ILE LEU VAL ASN
SEQRES 22 A 333 SER LYS PHE TYR LYS LEU VAL LYS ASP GLY TYR GLN MET
SEQRES 23 A 333 ALA GLN PRO ALA PHE ALA PRO LYS ASN ILE TYR SER ILE
SEQRES 24 A 333 MET GLN ALA CYS TRP ALA LEU GLU PRO THR HIS ARG PRO
SEQRES 25 A 333 THR PHE GLN GLN ILE CYS SER PHE LEU GLN GLU GLN ALA
SEQRES 26 A 333 GLN GLU ASP ARG ARG GLU ARG ASP
HET SO4 A 1 5
HET SO4 A 2 5
HET SO4 A 4 5
HET IXH A 923 38
HETNAM SO4 SULFATE ION
HETNAM IXH 8-(2,3-DIHYDRO-1H-INDEN-5-YL)-2-({4-[(3R,5S)-3,5-
HETNAM 2 IXH DIMETHYLPIPERAZIN-1-YL]PHENYL}AMINO)-5-OXO-5,8-
HETNAM 3 IXH DIHYDROPYRIDO[2,3-D]PYRIMIDINE-6-CARBOXAMIDE
FORMUL 2 SO4 3(O4 S 2-)
FORMUL 5 IXH C29 H31 N7 O2
FORMUL 6 HOH *169(H2 O)
HELIX 1 1 ASN A 572 GLU A 576 5 5
HELIX 2 2 PRO A 578 ASN A 580 5 3
HELIX 3 3 HIS A 623 GLY A 641 1 19
HELIX 4 4 LEU A 671 SER A 679 1 9
HELIX 5 5 SER A 696 LYS A 772 1 22
HELIX 6 6 ALA A 780 ARG A 782 5 3
HELIX 7 7 ASN A 788 HIS A 790 5 3
HELIX 8 8 PHE A 797 ARG A 801 5 5
HELIX 9 9 ASP A 802 ASP A 806 5 5
HELIX 10 10 PRO A 818 MET A 822 5 5
HELIX 11 11 ALA A 823 ASP A 829 1 7
HELIX 12 12 THR A 833 SER A 850 1 18
HELIX 13 13 ASN A 862 ASP A 871 1 10
HELIX 14 14 PRO A 882 TRP A 893 1 12
HELIX 15 15 GLU A 896 ARG A 900 5 5
HELIX 16 16 THR A 902 ARG A 921 1 20
SHEET 1 A 2 LYS A 551 ILE A 552 0
SHEET 2 A 2 CYS A 774 ILE A 775 -1 O ILE A 775 N LYS A 551
SHEET 1 B 5 LEU A 582 ALA A 590 0
SHEET 2 B 5 GLY A 594 LEU A 604 -1 O GLU A 598 N GLY A 585
SHEET 3 B 5 ALA A 609 LEU A 618 -1 O VAL A 615 N VAL A 597
SHEET 4 B 5 LEU A 660 GLU A 664 -1 O THR A 663 N ALA A 614
SHEET 5 B 5 LEU A 649 CYS A 653 -1 N LEU A 650 O ILE A 662
SHEET 1 C 3 GLY A 669 ASP A 670 0
SHEET 2 C 3 VAL A 784 LEU A 786 -1 O LEU A 786 N GLY A 669
SHEET 3 C 3 ALA A 792 ILE A 794 -1 O LYS A 793 N LEU A 785
SHEET 1 D 2 ILE A 810 LYS A 812 0
SHEET 2 D 2 ALA A 815 LEU A 817 -1 O LEU A 817 N ILE A 810
SITE 1 AC1 3 ARG A 549 LYS A 551 ARG A 777
SITE 1 AC2 5 ARG A 676 ASN A 808 ASN A 854 HOH A 929
SITE 2 AC2 5 HOH A1086
SITE 1 AC3 6 LYS A 595 LYS A 619 SER A 620 GLN A 877
SITE 2 AC3 6 PRO A 882 LYS A 883
SITE 1 AC4 18 LEU A 588 GLY A 589 ALA A 614 LYS A 616
SITE 2 AC4 18 THR A 663 GLU A 664 TYR A 665 CYS A 666
SITE 3 AC4 18 GLY A 669 ASN A 673 SER A 679 LEU A 785
SITE 4 AC4 18 ASP A 796 PHE A 797 ALA A 800 ARG A 801
SITE 5 AC4 18 HOH A 938 HOH A 980
CRYST1 81.140 81.140 145.650 90.00 90.00 120.00 H 3 9
ORIGX1 1.000000 0.000000 0.000000 0.00000
ORIGX2 0.000000 1.000000 0.000000 0.00000
ORIGX3 0.000000 0.000000 1.000000 0.00000
SCALE1 0.012324 0.007115 0.000000 0.00000
SCALE2 0.000000 0.014231 0.000000 0.00000
SCALE3 0.000000 0.000000 0.006866 0.00000